Breaking News on MFN ‘Targets’ … and a Review of the Right’s Reaction to the Policy
Shares:
Programming Note: Cost Curve is off tomorrow, back Monday. If you’re looking to get a value fix, though, the Drug Channels webinar on 340B is tomorrow. The topic couldn’t be
I’m down in Miami this week for the Drug Channels Leadership Forum. If you’re here, say hi at the reception tonight. If you have a colleague that’s here, let me
As is tradition, Merck is out as the first company to talk about 2023 list- and net-price changes across its portfolio. The company dropped its annual Pricing Action Transparency Report